secwatch.observer — SEC 8-K summary
======================================

Issuer:     Accelerate Diagnostics, Inc (—)
CIK:        0000727207
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001104659-24-058698
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Accelerate Diagnostics reports preliminary Q1 net loss of $17.0M; Wave trial on track
--------------------------------------------------------------------------------

- Q1 net sales $2.9M (+4% YoY); gross margin 25% vs 36% due to lower capital instrument mix.
- Net loss $17.0M ($0.88 per share); cash used $9.0M net of financing, including ~$1M prepaid annual expenses.
- Pre-clinical trial site installed for Accelerate Wave system; Gram Positive PBC menu development begun.
- Contracts secured covering ~70% of U.S. Pheno base; 12 new Pheno instruments added; 348 revenue-generating instruments at quarter-end.
- SG&A fell to $5.7M from $10.1M; R&D to $5.2M from $7.0M; both reflect lower employee costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/0001104659-24-058698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/727207/000110465924058698/tm2413892d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer